• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Wednesday's After-Market Session

    6/5/24 4:31:22 PM ET
    $AZTR
    $CCM
    $CLDI
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Nursing Services
    Health Care
    Get the next $AZTR alert in real time by email

    Gainers

    • Anitra (AMEX:AZTR) shares increased by 6.5% to $0.18 during Wednesday's after-market session. The market value of their outstanding shares is at $5.1 million.
    • Oragenics (AMEX:OGEN) shares increased by 4.24% to $2.04. The market value of their outstanding shares is at $9.1 million.
    • PACS Group (NYSE:PACS) shares rose 3.95% to $31.52. The market value of their outstanding shares is at $4.8 billion.
    • MultiPlan (NYSE:MPLN) shares moved upwards by 3.49% to $0.45. The market value of their outstanding shares is at $290.3 million.
    • Nanoviricides (AMEX:NNVC) stock moved upwards by 2.01% to $2.48. The market value of their outstanding shares is at $29.2 million.
    • Calidi Biotherapeutics (AMEX:CLDI) shares increased by 0.95% to $0.21. The company's market cap stands at $10.7 million.

    Losers

    • Matinas BioPharma Hldgs (AMEX:MTNB) shares decreased by 4.2% to $0.15 during Wednesday's after-market session. The market value of their outstanding shares is at $38.7 million.
    • Theriva Biologics (AMEX:TOVX) stock declined by 3.19% to $0.27. The company's market cap stands at $4.6 million.
    • Concord Medical Services (NYSE:CCM) stock fell 2.66% to $1.1. The company's market cap stands at $47.7 million.
    • Emergent BioSolutions (NYSE:EBS) shares fell 2.4% to $6.51. The market value of their outstanding shares is at $341.1 million.
    • Senseonics Holdings (AMEX:SENS) stock declined by 2.28% to $0.43. The company's market cap stands at $228.2 million.
    • Vicarious Surgical (NYSE:RBOT) stock declined by 2.16% to $0.35. The company's market cap stands at $61.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $AZTR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AZTR
    $CCM
    $CLDI
    $EBS

    CompanyDatePrice TargetRatingAnalyst
    PACS Group Inc.
    $PACS
    12/17/2025$44.00Overweight
    Analyst
    NanoViricides Inc.
    $NNVC
    12/16/2025Buy
    Alliance Global Partners
    Senseonics Holdings Inc.
    $SENS
    10/21/2025$9.00Hold
    Stifel
    Senseonics Holdings Inc.
    $SENS
    8/27/2025$1.50Overweight
    Barclays
    Senseonics Holdings Inc.
    $SENS
    7/15/2025$1.25Buy
    TD Cowen
    Senseonics Holdings Inc.
    $SENS
    6/2/2025$1.10Buy
    H.C. Wainwright
    Senseonics Holdings Inc.
    $SENS
    4/10/2025$2.00Outperform
    Mizuho
    Emergent BioSolutions Inc.
    $EBS
    12/30/2024$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $AZTR
    $CCM
    $CLDI
    $EBS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Williams Paul Anthony

    4 - Emergent BioSolutions Inc. (0001367644) (Issuer)

    4/3/26 4:05:55 PM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Roeder Douglas A

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    4/2/26 5:15:14 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Prince Douglas S

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    4/2/26 5:15:12 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Analyst resumed coverage on PACS Group with a new price target

    Analyst resumed coverage of PACS Group with a rating of Overweight and set a new price target of $44.00

    12/17/25 9:24:40 AM ET
    $PACS
    Hospital/Nursing Management
    Health Care

    Alliance Global Partners initiated coverage on NanoViricides

    Alliance Global Partners initiated coverage of NanoViricides with a rating of Buy

    12/16/25 8:59:58 AM ET
    $NNVC
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stifel resumed coverage on Senseonics with a new price target

    Stifel resumed coverage of Senseonics with a rating of Hold and set a new price target of $9.00

    10/21/25 7:22:14 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Matinas BioPharma Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

    BEDMINSTER, N.J., April 03, 2026 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (the "Company") (NYSE:MTNB) announced today that on April 2, 2026, it received a notice (the "Notice") from the NYSE American LLC (the "NYSE American") stating that the Company is not in compliance with the NYSE American continued listing standards set forth in Section 1003(a)(i) of the NYSE American Company Guide (the "Company Guide") requiring a company to have stockholders' equity of at least $2.0 million if it has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years, Section 1003(a)(ii) of the Company Guide requiring a company to have stockholders' 

    4/3/26 5:00:00 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026

    SAN DIEGO, April 01, 2026 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE:CLDI) ("Calidi" or the "Company"), a biotechnology company pioneering the development of targeted genetic medicines, will present new data at the American Association of Cancer Research (AACR) annual meeting in San Diego, California from April 17-22, 2026. The Company will demonstrate new data on its approach of simultaneously activating T-cells while inducing the expression of T-cell engagers specifically in situ in the tumor microenvironment (TME). RedTail is Calidi's systemically delivered virotherapy platform designed to selectively target tumors, remodel the TME, and enable high-level expression of thera

    4/1/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Vicarious Surgical Completes Integrated Benchtop Testing of Full Surgical Instrument Suite for Ventral Hernia Repair

    WALTHAM, Mass., March 30, 2026 (GLOBE NEWSWIRE) -- Vicarious Surgical Inc. (OTCQB:RBOT), a next-generation robotics technology company seeking to transform minimally invasive surgery (the "Company"), today announced the successful completion of initial integrated benchtop testing for its full suite of surgical instruments, required for its anticipated first clinical indication of ventral hernia repair, marking an important step toward design validation, clinical readiness, and the Company's targeted design freeze milestone. This milestone represents the first system-level performance evaluation of the Company's three core instruments: needle drivers, fenestrated graspers, and monopolar sc

    3/30/26 4:15:00 PM ET
    $RBOT
    Industrial Specialties
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Roeder Douglas A bought $100,275 worth of shares (17,500 units at $5.73), increasing direct ownership by 17% to 119,731 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:45 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    President and CEO Goodnow Timothy T bought $99,733 worth of shares (17,225 units at $5.79), increasing direct ownership by 3% to 651,243 units (SEC Form 4)

    4 - Senseonics Holdings, Inc. (0001616543) (Issuer)

    3/16/26 10:44:00 AM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    Director Dilsaver Evelyn S bought $499,997 worth of shares (16,724 units at $29.90), increasing direct ownership by 278% to 22,739 units (SEC Form 4)

    4 - PACS Group, Inc. (0002001184) (Issuer)

    11/26/25 4:46:20 PM ET
    $PACS
    Hospital/Nursing Management
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    SEC Filings

    View All

    Matinas Biopharma Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits

    8-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    4/3/26 5:00:36 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Inc. filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - Calidi Biotherapeutics, Inc. (0001855485) (Filer)

    4/2/26 5:00:27 PM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 10-K filed by Matinas Biopharma Holdings Inc.

    10-K - Matinas BioPharma Holdings, Inc. (0001582554) (Filer)

    3/31/26 4:05:50 PM ET
    $MTNB
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    Financials

    Live finance-specific insights

    View All

    Theriva™ Biologics Reports Full-Year 2025 Operational Highlights and Financial Results

    - Advancing clinical development of VCN-01 for pancreatic ductal adenocarcinoma and retinoblastoma - - Licensed SYN-020 to Rasayana Therapeutics for development in multiple indications; up to $38 million in potential milestones plus royalties on commercial sales - - Cash and cash equivalents of $13.1 million as of December 31, 2025; recent capital raises increase cash to $15.2 million as of February 26, 2026 and provides cash runway into Q1 2027- ROCKVILLE, M.D., March 12, 2026 (GLOBE NEWSWIRE) -- Theriva™ Biologics, Inc. (NYSE:TOVX), a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need, today reported fin

    3/12/26 8:00:00 AM ET
    $TOVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Vicarious Surgical Receives Delisting Notice From NYSE

    Vicarious Surgical Inc. (NYSE:RBOT) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced that on March 3, 2026, it received a notice (the "Notice") from the New York Stock Exchange (the "NYSE") that the NYSE has commenced the process of delisting the Company's Class A common stock, par value $0.0001 per share (the "Common Stock"). Trading on the Company's Common Stock on the NYSE was suspended after market close on March 3, 2026. The NYSE has determined that the Company has fallen below the continued listing standard, requiring listed companies to maintain an average global market capitalization over a con

    3/4/26 7:00:00 AM ET
    $RBOT
    Industrial Specialties
    Health Care

    Senseonics Holdings, Inc. Reports Fourth Quarter and Full Year 2025 Financial Results

    Generated Q4 revenue of $14.3 million, an increase of 72% year-over-year Received CE Mark approval for commercialization of Eversense 365 in Europe Launched first Eversense 365 AID system integration, with twiist in the US GERMANTOWN, Md., March 02, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ:SENS) a medical technology company focused on the development, manufacturing and commercialization of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced fourth quarter 2025 financial results and provided a business update. Recent Highlights & Accomplishments Generated fourth quarter 2025 revenue of $14.3 million, an increase

    3/2/26 4:01:00 PM ET
    $SENS
    Medical/Dental Instruments
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Oragenics Inc.

    SC 13G/A - ORAGENICS INC (0001174940) (Subject)

    11/14/24 7:29:57 PM ET
    $OGEN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by PACS Group Inc.

    SC 13G - PACS Group, Inc. (0002001184) (Subject)

    11/14/24 5:15:49 PM ET
    $PACS
    Hospital/Nursing Management
    Health Care

    SEC Form SC 13G filed by PACS Group Inc.

    SC 13G - PACS Group, Inc. (0002001184) (Subject)

    11/14/24 5:15:15 PM ET
    $PACS
    Hospital/Nursing Management
    Health Care

    $AZTR
    $CCM
    $CLDI
    $EBS
    Leadership Updates

    Live Leadership Updates

    View All

    PACS Group, Inc. Appoints Dr. Patrick Conway, MD, MSc to Board of Directors

    Former CMS Deputy Administrator, Chief Medical Officer, and Current CEO of Optum Brings Unparalleled Clinical, Regulatory, and Healthcare Leadership to PACS Board PACS Group, Inc. (NYSE:PACS), one of the nation's largest and fastest-growing post-acute healthcare platforms, today announced the appointment of Patrick H. Conway, MD, MSc, to its Board of Directors. Dr. Conway's addition to the PACS Board represents a landmark appointment for the post-acute and skilled nursing industry — bringing to the boardroom a rare combination of hands-on clinical experience, transformative federal regulatory leadership, large-scale health system executive experience, and deep expertise in quality, value-

    3/5/26 9:00:00 AM ET
    $PACS
    Hospital/Nursing Management
    Health Care

    Emergent BioSolutions Announces Appointment of John D. Fowler, Jr. to Board of Directors

    GAITHERSBURG, Md., March 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of John D. Fowler, Jr. to its board of directors effective March 1, 2026. Mr. Fowler brings more than three decades of leadership experience across the healthcare and financial services sectors. He will serve on the Audit and Finance Committee. "We're pleased to welcome John to the board of directors at this important point in the company's ongoing turnaround and transformation," said Dr. Zsolt Harsanyi, Ph.D., chairman of the board. "John's deep experience in healthcare and financial markets will provide valuable insight as the company continues to execute against i

    3/3/26 8:00:00 AM ET
    $EBS
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Calidi Biotherapeutics Provides Corporate Update and Key Value Drivers for 2026

    Company intends to file an IND in Q4 2026 for its first RedTail lead candidate, CLD-401, a systemically delivered and targeted genetic medicine engineered to deliver high concentrations of IL-15 superagonist to the tumor microenvironment in patients with metastatic disease.Calidi expects to present proof of concept data demonstrating the versatility of the RedTail platform and expanding its oncology platform with new payloads including the simultaneous delivery of tumor-localized BiTEs alongside T-cell amplifiers.Calidi expects to present proof of concept data demonstrating the applicability of the RedTail platform in non-oncology indications. SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) --

    1/28/26 8:00:00 AM ET
    $CLDI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care